Identifying Youth as "At Risk" for Mental Health Problems May Be Less Stigmatizing Than the Symptoms

Posted Oct 20, 2015

Close

E-mail Article

Complete form to e-mail article…

Required fields are denoted by an asterisk (*) adjacent to the label.

Separate multiple recipients with a comma

Close

Sign-Up For Newsletters

Complete this form to sign-up for newsletters…

Required fields are denoted by an asterisk (*) adjacent to the label.

 
There is an emergent and promising field of research on schizophrenia prevention, yet little is known about the potential harm and risks inherent in identifying and labeling young people at risk. A study led by researchers at Columbia University’s Mailman School of Public Health and New York State Psychiatric Institute found that young people identified as at clinical risk for psychosis described feeling stigmatized by the symptoms that led them to seek help to a relatively stronger degree than the risk label, or the stigma of coming to a specialized clinic. The study is the first to address the separate effects of symptoms and labeling on stigma in young people identified as at clinical high risk for schizophrenia and related psychotic disorders. Findings are online in the journal Schizophrenia Research.
 
“The clinical high-risk state is an incredibly important advance in psychiatry that enables identification of at-risk youth prior to development of full psychosis,” said Lawrence H. Yang, Ph.D., associate professor of Epidemiology at the Mailman School of Public Health and first author. “We were able to distinguish feelings of stigma due to attending a specialized high-risk clinic from the stigma of having symptoms and experiences. While the stigma of symptoms and experiences appear greater, the results indicate that both forms of stigma provide targets for intervention.”
 
Fewer than 1 in 3 young people identified as at-risk develop psychosis. The vast majority, therefore, either has residual symptoms or improves entirely. “Because there is the risk of having ‘false positives,’ it is especially important to demonstrate that stigma induced by the ‘at risk’ label appears less than that of symptoms,” said Yang. “But even for the true positives—those 1 in 3 that do develop psychosis—it is important to learn that the stigma of symptoms is a relatively stronger contributor to stigma, as such it is precisely the stigma that would be reduced by early intervention.”
 
The new paper reports the findings from a prospective cohort study at the New York State Psychiatric Institute at Columbia University at the Center of Prevention and Evaluation, or COPE, a comprehensive program that offers treatment and resources to participants about early symptoms and risk of schizophrenia. Upon joining COPE through community identification in clinics and schools, young people were told that while they were at increased risk for psychosis as compared with the general population, it was likely that they would not develop psychosis. They were also told that if they did develop psychosis, they would receive immediate treatment, which tends to be effective. In this study, young people were asked about their stigma experiences on average about 11 months after they entered the COPE program.
  
“Regarding labeling-related stigma, our findings indicate that similar to other psychiatric conditions—awareness of stereotypes was relatively high, and feelings of shame were significant,” noted Yang. “However, the fact that there were also positive emotions associated with identification—such as increased relief and understanding—and with coming to a specialized high-risk clinic indicates the beneficial effects of being identified as clinical high-risk.”
 
“This study confirms that the young people we identified as at risk for psychosis were more troubled by the symptoms they were having than by any label given to them,” said Cheryl Corcoran, M.D., senior author and Columbia University assistant professor of Clinical Psychiatry and a research scientist at the New York State Psychiatric Institute. “We are also encouraged to learn how much these young people resist or disagree with pervasive negative stereotypes of psychosis or schizophrenia and that this relative lack of stigma associated with a risk label might mean that more young people will seek out the treatment and services they need. Our task then is to develop the best treatments we can to reduce the risk of psychosis, and make them widely available to the very teens and young adults who need them."
Source: Columbia University, https://www.mailman.columbia.edu/public-health-now/news/identifying-youth-%E2%80%9C-risk%E2%80%9D-mental-problems-may-be-less-stigmatizing-symptoms#sthash.IOkHQksg.dpuf
There is an emergent and promising field of research on schizophrenia prevention, yet little is known about the potential harm and risks inherent in identifying and labeling young people at risk. A study led by researchers at Columbia University’s Mailman School of Public Health and New York State Psychiatric Institute found that young people identified as at clinical risk for psychosis described feeling stigmatized by the symptoms that led them to seek help to a relatively stronger degree than the risk label, or the stigma of coming to a specialized clinic. The study is the first to address the separate effects of symptoms and labeling on stigma in young people identified as at clinical high risk for schizophrenia and related psychotic disorders. Findings are online in the journal Schizophrenia Research.
 
“The clinical high-risk state is an incredibly important advance in psychiatry that enables identification of at-risk youth prior to development of full psychosis,” said Lawrence H. Yang, Ph.D., associate professor of Epidemiology at the Mailman School of Public Health and first author. “We were able to distinguish feelings of stigma due to attending a specialized high-risk clinic from the stigma of having symptoms and experiences. While the stigma of symptoms and experiences appear greater, the results indicate that both forms of stigma provide targets for intervention.”
 
Fewer than 1 in 3 young people identified as at-risk develop psychosis. The vast majority, therefore, either has residual symptoms or improves entirely. “Because there is the risk of having ‘false positives,’ it is especially important to demonstrate that stigma induced by the ‘at risk’ label appears less than that of symptoms,” said Yang. “But even for the true positives—those 1 in 3 that do develop psychosis—it is important to learn that the stigma of symptoms is a relatively stronger contributor to stigma, as such it is precisely the stigma that would be reduced by early intervention.”
 
The new paper reports the findings from a prospective cohort study at the New York State Psychiatric Institute at Columbia University at the Center of Prevention and Evaluation, or COPE, a comprehensive program that offers treatment and resources to participants about early symptoms and risk of schizophrenia. Upon joining COPE through community identification in clinics and schools, young people were told that while they were at increased risk for psychosis as compared with the general population, it was likely that they would not develop psychosis. They were also told that if they did develop psychosis, they would receive immediate treatment, which tends to be effective. In this study, young people were asked about their stigma experiences on average about 11 months after they entered the COPE program.
  
“Regarding labeling-related stigma, our findings indicate that similar to other psychiatric conditions—awareness of stereotypes was relatively high, and feelings of shame were significant,” noted Yang. “However, the fact that there were also positive emotions associated with identification—such as increased relief and understanding—and with coming to a specialized high-risk clinic indicates the beneficial effects of being identified as clinical high-risk.”
 
“This study confirms that the young people we identified as at risk for psychosis were more troubled by the symptoms they were having than by any label given to them,” said Cheryl Corcoran, M.D., senior author and Columbia University assistant professor of Clinical Psychiatry and a research scientist at the New York State Psychiatric Institute. “We are also encouraged to learn how much these young people resist or disagree with pervasive negative stereotypes of psychosis or schizophrenia and that this relative lack of stigma associated with a risk label might mean that more young people will seek out the treatment and services they need. Our task then is to develop the best treatments we can to reduce the risk of psychosis, and make them widely available to the very teens and young adults who need them."
Source: Columbia University, https://www.mailman.columbia.edu/public-health-now/news/identifying-youth-%E2%80%9C-risk%E2%80%9D-mental-problems-may-be-less-stigmatizing-symptoms#sthash.IOkHQksg.dpuf
There is an emergent and promising field of research on schizophrenia prevention, yet little is known about the potential harm and risks inherent in identifying and labeling young people at risk. A study led by researchers at Columbia University’s Mailman School of Public Health and New York State Psychiatric Institute found that young people identified as at clinical risk for psychosis described feeling stigmatized by the symptoms that led them to seek help to a relatively stronger degree than the risk label, or the stigma of coming to a specialized clinic. The study is the first to address the separate effects of symptoms and labeling on stigma in young people identified as at clinical high risk for schizophrenia and related psychotic disorders. Findings are online in the journal Schizophrenia Research.
 
“The clinical high-risk state is an incredibly important advance in psychiatry that enables identification of at-risk youth prior to development of full psychosis,” said Lawrence H. Yang, Ph.D., associate professor of Epidemiology at the Mailman School of Public Health and first author. “We were able to distinguish feelings of stigma due to attending a specialized high-risk clinic from the stigma of having symptoms and experiences. While the stigma of symptoms and experiences appear greater, the results indicate that both forms of stigma provide targets for intervention.”
 
Fewer than 1 in 3 young people identified as at-risk develop psychosis. The vast majority, therefore, either has residual symptoms or improves entirely. “Because there is the risk of having ‘false positives,’ it is especially important to demonstrate that stigma induced by the ‘at risk’ label appears less than that of symptoms,” said Yang. “But even for the true positives—those 1 in 3 that do develop psychosis—it is important to learn that the stigma of symptoms is a relatively stronger contributor to stigma, as such it is precisely the stigma that would be reduced by early intervention.”
 
The new paper reports the findings from a prospective cohort study at the New York State Psychiatric Institute at Columbia University at the Center of Prevention and Evaluation, or COPE, a comprehensive program that offers treatment and resources to participants about early symptoms and risk of schizophrenia. Upon joining COPE through community identification in clinics and schools, young people were told that while they were at increased risk for psychosis as compared with the general population, it was likely that they would not develop psychosis. They were also told that if they did develop psychosis, they would receive immediate treatment, which tends to be effective. In this study, young people were asked about their stigma experiences on average about 11 months after they entered the COPE program.
  
“Regarding labeling-related stigma, our findings indicate that similar to other psychiatric conditions—awareness of stereotypes was relatively high, and feelings of shame were significant,” noted Yang. “However, the fact that there were also positive emotions associated with identification—such as increased relief and understanding—and with coming to a specialized high-risk clinic indicates the beneficial effects of being identified as clinical high-risk.”
 
“This study confirms that the young people we identified as at risk for psychosis were more troubled by the symptoms they were having than by any label given to them,” said Cheryl Corcoran, M.D., senior author and Columbia University assistant professor of Clinical Psychiatry and a research scientist at the New York State Psychiatric Institute. “We are also encouraged to learn how much these young people resist or disagree with pervasive negative stereotypes of psychosis or schizophrenia and that this relative lack of stigma associated with a risk label might mean that more young people will seek out the treatment and services they need. Our task then is to develop the best treatments we can to reduce the risk of psychosis, and make them widely available to the very teens and young adults who need them."
Source: Columbia University, https://www.mailman.columbia.edu/public-health-now/news/identifying-youth-%E2%80%9C-risk%E2%80%9D-mental-problems-may-be-less-stigmatizing-symptoms#sthash.IOkHQksg.dpuf

The information provided on the Achieve Solutions site, including, but not limited to, articles, quizzes, and other general information, is for informational purposes only and should not be treated as medical, health care, psychiatric, psychological or behavioral health care advice. Nothing contained on the Achieve Solutions site is intended to be used for medical diagnosis or treatment or as a substitute for consultation with a qualified health care professional. Please direct questions regarding the operation of the Achieve Solutions site to Web Feedback. If you have concerns about your health, please contact your health care provider.  ©2017 Beacon Health Options, Inc.

 

Close

  • Useful Tools

    Select a tool below

© 2017 Beacon Health Options, Inc.